World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website http://www.wjon.org

Original Article

Volume 2, Number 5, October 2011, pages 252-258

A Pilot Study of Chemoradiotherapy With Weekly Docetaxel for Thoracic Esophageal Carcinoma With T4 and/or M1 Lymph Node Metastasis

**Table 1.** Patient characteristics
Characteristic	n = 9
Age (years)
Median	66
Range	51-78
Gender
Female	1
Male	8
Performance status
0	7
1	2
UICC TNM stage
non-T4 M1 LYM	4
T4 M0	4
T4 M1 LYM	1
Primary tumor site
Upper thoracic esophagus	3
Middle thoracic esophagus	5
Lower thoracic esophagus	1
Site of M1 LYM disease
Cervical node	4
Cervical and abdominal node	1

Table 1. Patient characteristics

Characteristic

n = 9

Age (years)

Median

Range

51-78

Gender

Female

Male

Performance status

UICC TNM stage

non-T4 M1 LYM

T4 M0

T4 M1 LYM

Primary tumor site

Upper thoracic esophagus

Middle thoracic esophagus

Lower thoracic esophagus

Site of M1 LYM disease

Cervical node

Cervical and abdominal node

**Table 2.** Summary of toxicity
	Grade (n = 9)	% ≥ Grade 3
Acute toxicity
Hematological
Leukopenia	8	0	1	0	0	0
Neutropenia	8	0	1	0	0	0
Anemia	4	3	1	0	0	0
Thrombocytopenia	8	0	1	0	0	0
Biochemical
Bilirubin	9	0	0	0	0	0
AST	7	2	0	0	0	0
ALT	7	2	0	0	0	0
Creatinine	8	1	0	0	0	0
Non-hematological
Anorexia	6	1	0	2	0	22
Nausea	9	0	0	0	0	0
Vomiting	8	0	1	0	0	0
Esophagitis	6	1	0	2	0	22
Esophageal bleeding	7	0	1	1	0	11
Dermatitis	7	1	1	0	0	0
Late toxicity
Peumonitis	9	0	0	0	0	0
Pleural effusion	8	0	0	1	0	11
Pericardial effusion	9	0	0	0	0	0

Table 2. Summary of toxicity

Grade (n = 9)

% ≥ Grade 3

Acute toxicity

Hematological

Leukopenia

Neutropenia

Anemia

Thrombocytopenia

Biochemical

Bilirubin

AST

ALT

Creatinine

Non-hematological

Anorexia

Nausea

Vomiting

Esophagitis

Esophageal bleeding

Dermatitis

Late toxicity

Peumonitis

Pleural effusion

Pericardial effusion

**Table 3.** Treatment response and prognosis of 9 patients
Case No.	Age	Gender	UICC TNM	Tumor site	Tumor size (cm)	Overall response	Primary response	Prognosis
PD, progressive disease; CR, complete response; PR, partial response; IR, incomplete response; SD, stable disease.
1	54	M	T4 M0	Middle	8	PD	PD	8 M died of disease
2	78	M	T4 M0	Upper	12	CR	CR	27 M died of esophageal perforation
3	60	M	T4 M0	Middle	15	PD	PD	2 M died of disease
4	51	M	T1 M1 LYM	Lower	5	PD	CR	36 M alive with disease progression
5	66	M	T1 M1 LYM	Middle	3	PR	CR	29 M died of disease
6	66	F	T3 M1 LYM	Middle	12	CR	CR	16 M died of disease
7	70	M	T3 M1 LYM	Middle	10	PR	IR/SD	5 M alive with disease progression
8	58	M	T4 M1 LYM	Upper	6	PR	IR/SD	9 M died of disease
9	70	M	T4 M0	Upper	13	PR	IR/SD	4 M died of disease

Table 3. Treatment response and prognosis of 9 patients

Case No.

Age

Gender

UICC TNM

Tumor site

Tumor size (cm)

Overall response

Primary response

Prognosis

PD, progressive disease; CR, complete response; PR, partial response; IR, incomplete response; SD, stable disease.

T4 M0

Middle

8 M died of disease

T4 M0

Upper

27 M died of esophageal perforation

T4 M0

Middle

2 M died of disease

T1 M1 LYM

Lower

36 M alive with disease progression

T1 M1 LYM

Middle

29 M died of disease

T3 M1 LYM

Middle

16 M died of disease

T3 M1 LYM

Middle

IR/SD

5 M alive with disease progression

T4 M1 LYM

Upper

IR/SD

9 M died of disease

T4 M0

Upper

IR/SD

4 M died of disease

**Table 4.** Summary of response and survival
Number of patients	9
CR, complete response; PR, partial response; CI, confidence interval.
Response rate	67% (CR 22%; PR 44%)
Median survival time	16.2 months (95% CI: 4.9-27.5)
2-year survival rate	38.9%

Table 4. Summary of response and survival

Number of patients

CR, complete response; PR, partial response; CI, confidence interval.

Response rate

67% (CR 22%; PR 44%)

Median survival time

16.2 months (95% CI: 4.9-27.5)

2-year survival rate

38.9%